Results 221 to 230 of about 43,170 (263)

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

Drugs, 2011
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire   +2 more sources

Highlight: Dipeptidyl peptidase 4 and related proteins

Biological Chemistry, 2011
No abstract ...
Torsten, Hoffmann, Hans-Ulrich, Demuth
openaire   +2 more sources

Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

Diabetes/Metabolism Research and Reviews, 2020
AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen, Charlotte B. Holt, Lisbeth Jensen, Camilla Hage, Linda G. Mellbin, Steffen Thiel, Troels K. Hansen, Jakob A. Østergaard   +7 more
openaire   +3 more sources

Renal outcomes with dipeptidyl peptidase-4 inhibitors

Diabetes & Metabolism, 2018
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire   +3 more sources

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

Clinical Therapeutics, 2011
Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Kathleen R, Richard, Jamie S, Shelburne, Julienne K, Kirk   +2 more
openaire   +2 more sources

Dipeptidyl peptidase-4 inhibition and renoprotection

Current Opinion in Nephrology and Hypertension, 2017
This article analyzes the potential beneficial effects of dipeptidyl peptidase (DPP)-4 inhibitors on renal diseases.The pathological significance of DPP-4, either dependent or independent on catalytic activities, on renal diseases has been reported in preclinical studies.
Yuta, Takagaki, Daisuke, Koya, Keizo, Kanasaki   +2 more
openaire   +2 more sources

Dipeptidyl peptidase-4 inhibitors

2016
Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire   +1 more source

Dipeptidyl-peptidase-4-inhibitors

Reactions Weekly, 2023
openaire   +1 more source

Dipeptidyl Peptidase-4

RCSB Protein Data Bank, 2016
openaire   +2 more sources

Dipeptidyl Peptidase-4 – A Comprehensive Review

Current Enzyme Inhibition
Type 2 diabetes mellitus is a growing global public health issue, with its prevalence projected to increase in the coming decades. It is one of the most prevalent and growing global health concerns, affecting millions of individuals worldwide. The condition is classified into two primary types: Type 1 diabetes,
Venkatesan Parthasarathi, Hemalatha Kanagarajan   +1 more
openaire   +1 more source